238 related articles for article (PubMed ID: 33093447)
1. Targeting N-myristoylation for therapy of B-cell lymphomas.
Beauchamp E; Yap MC; Iyer A; Perinpanayagam MA; Gamma JM; Vincent KM; Lakshmanan M; Raju A; Tergaonkar V; Tan SY; Lim ST; Dong WF; Postovit LM; Read KD; Gray DW; Wyatt PG; Mackey JR; Berthiaume LG
Nat Commun; 2020 Oct; 11(1):5348. PubMed ID: 33093447
[TBL] [Abstract][Full Text] [Related]
2. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
[TBL] [Abstract][Full Text] [Related]
3. Myristoylation of Src kinase mediates Src-induced and high-fat diet-accelerated prostate tumor progression in mice.
Kim S; Yang X; Li Q; Wu M; Costyn L; Beharry Z; Bartlett MG; Cai H
J Biol Chem; 2017 Nov; 292(45):18422-18433. PubMed ID: 28939770
[TBL] [Abstract][Full Text] [Related]
4. Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression.
Kim S; Alsaidan OA; Goodwin O; Li Q; Sulejmani E; Han Z; Bai A; Albers T; Beharry Z; Zheng YG; Norris JS; Szulc ZM; Bielawska A; Lebedyeva I; Pegan SD; Cai H
Cancer Res; 2017 Dec; 77(24):6950-6962. PubMed ID: 29038344
[TBL] [Abstract][Full Text] [Related]
5. Multiomics analysis identifies oxidative phosphorylation as a cancer vulnerability arising from myristoylation inhibition.
Beauchamp E; Gamma JM; Cromwell CR; Moussa EW; Pain R; Kostiuk MA; Acevedo-Morantes C; Iyer A; Yap M; Vincent KM; Postovit LM; Julien O; Hubbard BP; Mackey JR; Berthiaume LG
J Transl Med; 2024 May; 22(1):431. PubMed ID: 38715059
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of protein N-myristoylation: a therapeutic protocol in developing anticancer agents.
Das U; Kumar S; Dimmock JR; Sharma RK
Curr Cancer Drug Targets; 2012 Jul; 12(6):667-92. PubMed ID: 22463587
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
8. Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Battistello E; Katanayeva N; Dheilly E; Tavernari D; Donaldson MC; Bonsignore L; Thome M; Christie AL; Murakami MA; Michielin O; Ciriello G; Zoete V; Oricchio E
Blood; 2018 May; 131(21):2345-2356. PubMed ID: 29567799
[TBL] [Abstract][Full Text] [Related]
9. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
10. Steroid receptor coactivator-3 is a pivotal target of gambogic acid in B-cell Non-Hodgkin lymphoma and an inducer of histone H3 deacetylation.
Zhao Z; Zhang X; Wen L; Yi S; Hu J; Ruan J; Zhao F; Cui G; Fang J; Chen Y
Eur J Pharmacol; 2016 Oct; 789():46-59. PubMed ID: 27370960
[TBL] [Abstract][Full Text] [Related]
11. Validation and Invalidation of Chemical Probes for the Human N-myristoyltransferases.
Kallemeijn WW; Lueg GA; Faronato M; Hadavizadeh K; Goya Grocin A; Song OR; Howell M; Calado DP; Tate EW
Cell Chem Biol; 2019 Jun; 26(6):892-900.e4. PubMed ID: 31006618
[TBL] [Abstract][Full Text] [Related]
12. N-terminal N-myristoylation of proteins: refinement of the sequence motif and its taxon-specific differences.
Maurer-Stroh S; Eisenhaber B; Eisenhaber F
J Mol Biol; 2002 Apr; 317(4):523-40. PubMed ID: 11955007
[TBL] [Abstract][Full Text] [Related]
13. Use of alkyne-tagged myristic acid to detect N-terminal myristoylation.
Xu Y; Lin H
Methods Enzymol; 2023; 684():191-208. PubMed ID: 37230589
[TBL] [Abstract][Full Text] [Related]
14. N-Myristoyltransferase Inhibition Induces ER-Stress, Cell Cycle Arrest, and Apoptosis in Cancer Cells.
Thinon E; Morales-Sanfrutos J; Mann DJ; Tate EW
ACS Chem Biol; 2016 Aug; 11(8):2165-76. PubMed ID: 27267252
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib inhibits pre-BCR
Kim E; Hurtz C; Koehrer S; Wang Z; Balasubramanian S; Chang BY; Müschen M; Davis RE; Burger JA
Blood; 2017 Mar; 129(9):1155-1165. PubMed ID: 28031181
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
17. Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis.
Ducker CE; Upson JJ; French KJ; Smith CD
Mol Cancer Res; 2005 Aug; 3(8):463-76. PubMed ID: 16123142
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.
Yang C; Lu P; Lee FY; Chadburn A; Barrientos JC; Leonard JP; Ye F; Zhang D; Knowles DM; Wang YL
Leukemia; 2008 Sep; 22(9):1755-66. PubMed ID: 18596745
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression and Aberrant T Cell Development in the Absence of N-Myristoylation.
Rampoldi F; Bonrouhi M; Boehm ME; Lehmann WD; Popovic ZV; Kaden S; Federico G; Brunk F; Gröne HJ; Porubsky S
J Immunol; 2015 Nov; 195(9):4228-43. PubMed ID: 26423150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
